The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Novel Therapies in Hepatic Encephalopathy
Clin Liver Dis. 2020 May;24(2):303-315.doi: 10.1016/j.cld.2020.01.009.Epub 2020 Mar 2.
Maryam Alimirah 1, Omar Sadiq 2, Stuart C Gordon
Author information
1Department of Internal Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, CFP-1, Detroit, MI 48202, USA.
2Department of Gastroenterology and Hepatology, Henry Ford Hospital, 2799 West Grand Boulevard, K7, Detroit, MI 48202, USA.
3Department of Gastroenterology and Hepatology, Henry Ford Hospital, 2799 West Grand Boulevard, K7, Detroit, MI 48202, USA; Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: sgordon3@hfhs.org.
Abstract
Despite widespread use of lactulose and rifaximin for the treatment of hepatic encephalopathy, this complication of advanced liver disease remains a major burden on the health care system in the United States and continues to predispose to high morbidity and mortality. Several agents have surfaced over recent years with promise to treat hepatic encephalopathy and mitigate the cognitive impairment associated with this disease process. The purpose of this article is to highlight the leading emerging therapies in hepatic encephalopathy as well as their therapeutic targets.